几丁糖联合小剂量糖皮质激素关节腔注射治疗早中期膝骨关节炎的临床疗效分析
DOI:
作者:
作者单位:

1.南京医科大学第一附属医院(江苏省人民医院)骨科;2.南京中医药大学附属医院(江苏省中医院)风湿免疫科

作者简介:

通讯作者:

中图分类号:

基金项目:

2022年度省中医药科技发展计划项目立项计划表一青年人才项目


Analysis of the clinical efficacy of intra-articular injection of chitosan combined with low-dose corticosteroids in the treatment of knee osteoarthritis in early and middle stages
Author:
Affiliation:

Department of Orthopedics Surgery, the First Affiliated Hospital of Nanjing Medical University(Jiangsu Province Hospital)

Fund Project:

2022 Jiangsu Traditional Chinese Medicine Science and Technology Development Plan Project-Young Talents Project

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:探讨几丁糖联合小剂量糖皮质激素关节腔注射治疗早中期膝骨关节炎的临床疗效。方法:回顾性分析2021年6月—2022年12月在南京医科大学第一附属医院骨科门诊就诊并随访的膝骨关节炎患者共164例。按治疗方式分为3组:A组(对照组,口服给药)55例,B组(几丁糖关节腔注射+口服给药)53例,C组(几丁糖联合小剂量糖皮质激素关节腔注射给药)56例。比较3组治疗前后的疼痛视觉模拟评分(visual analogue scale, VAS)、Lysholm评分、美国特种外科医院 (Hospital for Special Surgery, HSS)评分和关节液炎性细胞因子白介素(interleukin, IL)-1、IL-6和肿瘤坏死因子(tumor necrosis factor, TNF)-α水平的变化,并对临床疗效进行评价。结果:所有病例均获得随访,随访时间7-12个月,无失访病例。每组治疗后的VAS评分、Lysholm评分、HSS评分和关节液炎性细胞因子IL-1、IL-6和TNF-α水平均优于治疗前,差异有统计学意义(P<0.05)。治疗前3组VAS评分、Lysholm评分、HSS评分和关节液炎性细胞因子IL-1、IL-6和TNF-α水平,差异无统计学意义(P>0.05);但治疗后3组各项指标差异有统计学意义(P<0.05);两两比较显示,C组优于A、B两组,B组优于A组,差异均有统计学意义(P<0.05)。3组临床疗效评价比较,差异有统计学意义(P<0.05)。结论:几丁糖联合小剂量糖皮质激素关节腔注射治疗早中期膝骨关节炎临床疗效显著,具有创伤小,起效迅速,疗效持久的特点,同时避免了外用或口服非甾体类抗炎药的不良反应,作为一线治疗方案,建议在临床推广和使用。

    Abstract:

    Objective: To investigate the clinical efficacy of intra-articular injection of chitosan combined with low-dose corticosteroids in the treatment of knee osteoarthritis in early and middle stages.Methods: A retrospective analysis was conducted on 164 patients with knee osteoarthritis who visited and were followed up at the outpatient department of orthopedics at the First Affiliated Hospital of Nanjing Medical University from June 2021 to December 2022.Based on the treatment methods, patients were divided into three groups: Group A(Control Group,Oral administration) consisted of 55 patients, Group B(Intra-articular injection of chitosan+Oral administration) had 53 patients, Group C(Intra-articular injection of chitosan combined with low-dose glucocorticoids) included 56 patients.Variations in pain visual analogue scale(VAS) , Lysholm score, Hospital for Special Surgery (HSS) score, and the levels of inflammatory cytokines in the synovial fluid (interleukin-1, IL-1; interleukin-6, IL-6; tumor necrosis factor-alpha, TNF-α) were compared before and after treatment.Clinical efficacy was also evaluated.Results: All cases were followed up for 7-12 months and no cases were lost. Post-treatment VAS scores, Lysholm scores, HSS scores and the levels of synovial fluid inflammatory cytokines (IL-1, IL-6, and TNF-α) were all significantly improved compared to pre-treatment levels in each group (P<0.05).There were no significant differences in pre-treatment VAS scores, Lysholm scores, HSS scores and the levels of IL-1, IL-6, and TNF-α among the three groups(P>0.05);however, post-treatment comparisons showed significant differences (P<0.05). Compared with each other, Group C showed better outcomes than Groups A and B, and Group B was superior to Group A, with significant statistical differences (P<0.05).The comparison of clinical efficacy among the three groups also showed statistically significant differences (P<0.05).Conclusion: Intra-articular injection of chitosan combined with low-dose corticosteroids shows significant clinical efficacy in the treatment of knee osteoarthritis in early and middle stages, with the advantages of minimal trauma,rapid onset,lasting efficacy and avoids the adverse reactions of external application or oral administration of non-steroidal anti-inflammatory drugs. As a first-line treatment option, its clinical promotion and use are recommended.

    参考文献
    相似文献
    引证文献
引用本文
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2024-03-17
  • 最后修改日期:2024-06-18
  • 录用日期:2024-08-08
  • 在线发布日期:
  • 出版日期:
关闭